CEO, Partner: Paul C. Dreier, BSc., MBA
Dreier has over 20 years of experience in the start-up, marketing, and managing of companies that provide software and instruments to the pharmaceutical and government sectors. He started his career as a chemist and product development manager, eventually working his way into the management field on an international basis. Dreier has held equity positions in various successful exits. He served in various positions, including leading one exit including:
Camile Products – Software and instruments in pharmaceutical chemistry - Sold for over $10M
Argonaut Technologies – Instruments for pharmaceutical chemistry - Sold to Biotage AB
PartTec, Ltd. – Neutron detection instruments for medical, defense, and research - Sold to GE (now Baker Hughes Digital)
He also started, merged, and has been the general manager for four international sales and service centers outside of America. Dreier successfully obtained seed capital to start a new $12M start-up division in the biochemistry instrument market. He is a founder and current Chairman of the Board for zWorks, an incubator that has raised over $26M for Indiana start-ups.
He gives back to many charities and as an executive mentor at the Purdue Foundry, the national leader in university entrepreneurship programs.
CTO, Partner: Fred E. Regnier, Ph.D.
Regnier founded Novilytic and joined as the Chief Executive Officer in 2014. The company was originally founded to develop medical device blood cards and methods and is successfully producing that product today. He has co-founded five analytical science companies including:
PerSeptive Biosystems (PBIO) – Analytical and clinical preparative tools - Sold to Applied Biosystems for $384M
BG Medicine (BGMD) – Diagnostic tests for heart failure - Publicly Traded
Quadraspec – Diagnostic products for the veterinary market - Sold to Antech
Dr. Regnier held the J.H. Law Distinguished Professor of Chemistry position at Purdue University. He has co-authored 306 peer-reviewed publications in the fields of chromatography, proteomics, and metabolomics and holds 47 patents in analytical and diagnostic science. Dr. Regnier was the Chief Scientific Officer at PBIO for 3 years, directing an R&D staff of ~100.
Co-Founder & Technical Counsel: Jiri Adamec, Ph.D.
Dr. Adamec is currently an Associate Professor at the Department of Biochemistry at the University of Nebraska – Lincoln. He also serves as a Director of Proteomics and Metabolomics Core Facilities at Redox Biology Center at UNL.
Dr. Adamec has co-authored more than 60 peer-reviewed publications and serves as a reviewer of Science and journals. Many of his publications focus on proteomic and metabolomics approaches to Systems Biology. Dr. Adamec worked at the Bindley Bioscience Center at Purdue University and was a member of their board prior to joining Novilytic.
COO & Partner: Timothy E. Woenker, BSc.
Timothy Woenker is a founding partner of Novilytic and has operational responsibility for, design implementation and manufacturing activities associated with the Noviplex product line.
As Director of Operations, and later as President of Chematics, Incorporated., Mr. Woenker has over 30 years of broad experience in the design and manufacture, registration, and approval of a variety of disposable Class I and II in-vitro diagnostic medical devices. Experience includes:
Manufacturing process development and process validation activities to support the manufacture of multiple disposable IVD devices.
Technical oversight, process development and process validation for 6 different IVDs.
Development and implementation of Quality Assurance Programs for compliance with FDA, cGMP, IVD manufacturing regulations under 21CFR Part 820 regulations for 6 individual IVD products.
Directed clinical trials to support data generation, compilation and reporting of results from performance studies for FDA 510(k) clearance of four separate in-vitro diagnostic devices.
Directed ISO-13485 Registration and CE marking of multiple IVD Products.
Responsible for the purchase, installation, development and operation of a 40L bioreactor process facility for the production and purification of a specific enzyme from yeast.